



April 28, 2009

Attention: **Secretary Janet Napolitano**
Department of Homeland Security
U.S. Department of Homeland Security
Washington, DC 20528
Tel: 1-202-647-4000
Fax: 1-202-647-2283

Re: ALERT: Treating Swine and Avian Flu by Down-Regulating Inflammatory Response

Dear Madam Secretary and Dr. Butler-Jones:

As I'm sure your office is aware, the influenza virus has a unique genetic make up that, in combination with its replicative machinery, has an extraordinary capacity to mutate. The high lethality of some strains can be attributed to the resulting adult respiratory distress syndrome (ARDS), which is caused by an excessive immune inflammatory response driven by Tumor Necrosis Factor (TNF). TNF leads to the death of respiratory epithelial cells and resulting edema and organ failure; victims drown in their own mucus, suffering pulmonary decline and subsequent systemic failures. Endocannabinoids are nature's way of controlling TNF activity.

Current anti-viral medical technology is now inadequate to meet our country's or the World's pressing challenges dealing with influenza. Dead or live virus inoculation does not currently appear capable of keeping up with the speedy mutations of the numerous influenza viruses. Through no fault of the medical research community, determining the strain that the widely available annual flu shot will cover is as much guesswork as science. Worse still, Roche acknowledges that Tamiflu (Oseltamivir) is not effective against Type A influenza, including the Swine Flu.

Our approach in the interim is to address the body's symptomatic responses to the ravages of the disease, giving the body's natural recovery processes the time and opportunity to work. Science and preliminary anecdotal results confirm the anti-inflammatory properties of our whole-cannabis lozenge and indicate it may present an effective and non-toxic treatment for minimizing the symptoms and harm from influenza infections. The lozenge appears to down-regulate the body's excessive inflammatory response to the influenza virus, which could reduce the deadly consequences of an infection into something that is more like a common cold. This is Nature finding a way differently, through an effective, socially acceptable man-made application of a natural botanical cure.



Based upon recent discoveries regarding the role that endocannabinoid system plays in maintaining human health, we believe our whole cannabis-extract lozenge is a unique solution to the looming threat posed by deadly influenza strains. We propose that a public health campaign based on use of our lozenge could save millions of lives, especially in considering that current anti-influenza medications have a demonstrated decreased effectiveness against some of these lethal variants.

The lozenge has not yet been tested by the FDA or approved for use in the U.S. by any other agency of the U.S. Government. However, medicinal cannabis use dates back almost 5,000 years, and no one has ever asserted cannabis is toxic; nobody has ever died from cannabis use. We are arranging researchers and other professionals for the IND process, and currently intend to utilize the Orphan Drug Act to seek approval of our lozenge for treatment of specialized forms of cancer like the one I suffer, but our Company isn't there yet.

While we would obviously like to be farther along in this process, the current health crisis demands immediate action. We now offer your Department our lozenge for use to deal with the current scourge.

You should feel free to contact me, if you have any questions about our Company, its lozenge, our team, or this proposal. Dr. Melamede has also asked that I extend to your Department his willingness to assist directly with regard to cannabis applications for HN1 Swine Flue and H5N1 Bird Flu.

I look forward to your response.

Very Truly Yours,

A handwritten signature in blue ink that reads "Steve Kubby". The signature is fluid and cursive, with the first letters of the first and last names being capitalized and prominent.

Steve Kubby,
President & CEO
Cannabis Science Inc.
NASD OTCBB: GFON

Suite 16645
548 Market Street
San Francisco CA 94104

www.cannabisscience.com
info@cannabisscience.com

Tel: 1.888.889.0888
Fax: 1.866.943.5085